Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). According to GlobalData, Phase II drugs for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Bevacizumab biosimilar LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bevacizumab biosimilar overview
Bevacizumab (Byvasda) is a recombinant humanized monoclonal IgG1 antibody, acts as an anti-neoplastic agent. It is formulated as injectable solution for intravenous route of administration. Byvasda is indicated for the treatment of patients with advanced non-small cell lung cancer and metastatic colorectal cancer.
Bevacizumab biosimilar (IBI-305) is under development for the treatment of recurrent endometrial cancer, hepatocellular carcinoma (HCC), hepatocellular carcinoma and Recurrent respiratory papillomatosis. The therapeutic candidate is administered through intravenous infusion route. It acts by targeting VEGF-A.
The drug candidate was also under development for non-small cell lung cancer, metastatic colorectal cancer, gastric cancer and non-squamous non-small cell lung cancer.
Innovent Biologics overview
Innovent Biologics is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for therapeutic areas such as oncology, cardiovascular and metabolic diseases, autoimmune diseases, and ophthalmology. The company’s oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, ramucirumab, and others. Innovent Biologics‘s autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311 IGF-1R and IBI-333, among others. It markets products under brands TYVYT, BYVASDA, SULINNO, HALPRYZA, Pemazyre, Cyramza, Retsevmo, FUCASO, and SINTBILO. The company operates in China, the US, the UK, Japan, Australia, Canada and Korea. Innovent Biologics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
